FDA and PDG Host Joint DSCSA Midpoint Review to Surface Interoperability Gaps Across Trading Partners

Interoperability gaps in pharmaceutical supply chain tracing remain the central unresolved challenge as FDA and the Partnership for DSCSA Governance (PDG) convene a joint public meeting on June 17–18, 2024, to assess where industry stands at the midpoint of the DSCSA stabilization period. For supply chain directors and plant heads, the meeting represents a structured opportunity to benchmark their own implementation progress against what trading partners are reporting to regulators.

The two-day session, held at 601 New Jersey Ave. NW, Washington, DC, is structured explicitly as a checkpoint, not a rulemaking event, designed to surface remaining gaps before full enforcement obligations take effect. FDA's framing draws directly from its earlier request for information on implementing interoperable systems under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act, and PDG will layer in aggregated industry progress data collected from member trading partners. The combination gives regulators and operators a consolidated read on where electronic product tracing is functioning and where it is not.

Stakeholder groups presenting at the meeting are expected to address stabilization activity still outstanding, areas of concern around system interoperability, and the steps needed to achieve enhanced drug distribution security at scale. Individuals and organizations sharing common positions are encouraged to consolidate presentations; time per presenter will be allocated based on total requests received, and no same-day oral presentation registration will be accepted.

Both in-person and virtual attendance are subject to capacity limits, with allocation prioritised in registration order, though PDG and FDA reserve the right to rebalance attendance to ensure representative trading partner perspectives are heard. In-person confirmations were scheduled for email by May 14, 2024; virtual participation details by May 31, 2024. Travel costs remain the responsibility of individual attendees.

For QA directors and regulatory affairs leads, the sharper read is on documentation: insights surfaced at this meeting are likely to inform FDA's posture on compliance expectations as the stabilization window closes, making it a material input for any organisation still reconciling its serialisation and tracing architecture against the full DSCSA requirements.

The measurable outcome to track is whether PDG's aggregated industry progress data, presented alongside FDA's RFI findings, produces a revised set of prioritised interoperability actions that trading partners will be expected to close before the stabilization period ends.

Source: FDA via What's New: Drugs RSS Feed, published 2026-08-28; meeting dates June 17–18, 2024.